肠易激综合征护理干预措施探讨

目的:探讨护理干预对肠易激综合征(IBS)患者心理状况的改善.方法:对40例肠易激综合征(IBS)患者进行包括护理干预,采用焦虑自评量表(SAS)和抑郁自评量表(SDS)其进行评估.结果:IBS患者干预后SAS、SDS得分较干预前明显降低(P＜0.05).结论:护理干预可改善患者的心理状态,增强心理应对能力.     

肠易激综合征病人心理特征及护理

肠易激综合征(IBS)是一种胃肠功能紊乱性疾病,其临床特点是持续存在或间歇发作的腹痛、腹胀、便秘或腹泻交替出现,使病人的生理功能发生了明显的病理变化,心理上也随之表现了焦虑、恐惧等心理特征。 1 临床资料 我院从1998年6月～2001年12月,按照国内制定的肠易     

肠易激综合征的中医护理

肠易激综合征是临床上常见的消化系统功能性疾病，与肠道动力学异常有关。其发病机制目前不详。作者试图根据中医的病因病机特点及其中医临床护理特点，对肠易激综合征的护理疗法及预后调护进行系统的阐述，以提高临床疗效及护理水平。     

86例肠易激综合征患者贝飞达治疗效果分析

肠易激综合征（IBS）是一种常见的消化系统疾病。近年来有学者注意到肠腔内菌群失调在IBS发病机制中的重要地位。本文就贝飞达治疗86例IBS中的作用做初步分析，以观察益生菌及其产物治疗IBS的可行性。[第一段]     

肠易激综合征临床分析

目的 探讨肠易激综合征（IBS）的病因、发病情况及其相关临床特征。方法连续收集问卷普通内科门诊及消化专科门诊IBS 826例。结果IBS患者女性显著多于男性。发病高峰年龄段为25～55岁；中等文化水平者（60.2％）惠病就医比例最高。结论IBS患者的高峰年龄段较国外报道提前，IBS患病率高低与患者受教育程度不成正比例关系，不同于国外报道。     

对女性肠易激综合征患者进行健康教育的效果评价

[目的]IBS患者但尚无满意的治疗方法.本研究旨在评价对女性IBS患者进行健康教育的效果.[方法]采用自身对照研究,IBS-36量表对IBS患者进行相关生存质量(health-related QOL,HR-QoL)评分.对33例女性IBS患者进行积极的健康教育,评价基线为干预前2月的评分,评价终点为干预后3月的评分.[结果]共33例患者进入基线评价,31例患者完成健康教育全过程和干预后3月的评价.干预后IBS-36评分比干预前明显下降,(25.5±6.5)vs(16.6±5.9)分(P＜0.01).对腹痛和排便异常两个单项进行比较,干预后的评分也比干预前明显下降(分别3.6±1.3 vs 2.1±0.9和3.1±1.2 vs 1.3±1.1,两者P＜0.001).[结论]健康教育可在短期内缓解或消除女性IBS患者的心理障碍和躯体症状,使患者的健康相关生存质量明显改善.     

肠易激综合征患者疾病认知情况调查

目的调查肠易激综合征（IBS）患者对疾病的认知情况。方法收集86例IBS患者进行问卷调查，然后根据各个调查问题进行患者数据汇总统计，并计算其占总例数的百分率。结果仅47．7％的患者听说过IBS，44．2％的患者认为IBS为肠道细菌感染性疾病。26．7％的患者认为IBS起源于急性胃肠炎。半数以上的患者认为IBS与心理因素．工作或生活压力、睡眠质量和食品有关。26．7％的患者认为诊断IBS需要长期反复进行结肠镜等检查，33．7％的患者认为仅使用药物就能治愈IBS。69．8％的患者认为IBS随着年龄增长会恶化，15．1％的患者认为IBS会发展为结肠癌。结论患者对IBS的知识了解有限，部分患者甚至观念错误。应加强对IBS患者的卫生知识宣教以提高IBS患者的生活质量。     

综合干预对肠易激综合征的临床疗效分析

目的：探讨综合干预配合药物治疗肠易激综合征（IBS）的临床效果。方法：符合标准的IBS患者200例,随机分为综合干预结合药物的综合组、单纯药物治疗的对照组,观察两组疗效、不良反应以厦随访期间药物依从性。结果：经过1个疗程后,综合组有效率96．00％,对照组为85．00％,差异具有显著性（P〈0．05）;综合组不良反应6例（6．oo％）,对照纽不良反应12例（12．00％）,差异显著（P〈0．05）。综合纽依从率为90．00％,对照鲤为70．D。％,两纽比较差异显著（P〈0．05）。结论：综合干预联合药物治疗IBs—D可有效降低不良反应,提高疗效及依从性,值得推广应用。     

肠易激综合征患者生活质量对照研究

目的了解肠易激综合征(IBS)患者生活质量状况.方法应用SF-36健康普适量表对25例符合罗马Ⅱ诊断标准的IBS患者及性别、年龄相匹配的健康对照者进行调查,作生活质量比较研究.结果 IBS患者除了生理功能(PF)外,其它7个维度的生活质量平均积分均比健康对照组低(生理职能P＜0.05,余6个维度均P＜0.01);IBS患者生活质量下降和肠道症状并不相关.结论 IBS患者生活质量普遍低下,但并非肠道症状直接影响所致.     

坦度螺酮治疗肠易激综合征疗效观察

目的 观察坦度螺酮治疗肠易激综合征患者的疗效.方法 将肠易激综合征患者分为两组,对照组根据患者不同症状给予对症治疗,治疗组在对照组治疗基础上给予坦度螺酮治疗,疗程均为4周.观察比较治疗前后两组患者主要躯体症状、情绪状态的改变,采用焦虑自评量表（SAS）与抑郁自评量表（SDS）分别对其焦虑、抑郁状况进行评估.结果 治疗组患者躯体症状改善效果优于对照组;治疗组SAS评分明显低于对照组,两组SDS评分差异未见明显统计学意义.结论 肠易激综合征患者,坦度螺酮对于缓解其躯体与情绪症状,改善生存质量具有重要意义.     

肠易激综合征回盲部肥大细胞的实验观察

目的观察肠易激综合征(IBS)患者肠黏膜回盲部肥大细胞的分布及变化,探讨其在IBS中的可能作用。方法符合入选标准IBS患者30例,按临床症状分为腹泻型、便秘型。与15例正常人经结肠镜钳取回盲部结肠黏膜,检测肥大细胞及脱颗粒肥大细胞的数目,进行比较。结果IBS患者回盲部肥大细胞的数目增多,与正常对照组比较,有高度统计学意义,腹泻型与便秘型之间差异无统计学意义;腹泻型、便秘型患者回盲部脱颗粒肥大细胞数明显多于正常组,差异有统计学意义;便秘型与腹泻型之间比较P<0.01,有高度统计学意义。结论肠易激综合征患者回盲部肥大细胞增多,提示与IBS临床症状有相关性;腹泻型肠易激综合征回盲部脱颗粒肥大细胞增多,提示肥大细胞活化是产生IBS腹泻的原因。     

北京地区肠易激综合征的流行病学研究:一个整群、分层、随机的调查

目的 对北京市肠易激综合征（ＩＢＳ）的患病率及危险因素进行研究。方法 用整群、分层、单纯随机抽样方法,对北京市常住人口中１８￣７０岁的２４８６人进行问卷调查作为初筛,了解按Ｍａｎｎｉｎｇ标准加以补充及按罗马标准判断的有症状人群的检出率,再对筛出有症状的部分人在医院进行以排除结肠器质性疾病为目的的精查,根据精查的正确率对普查结果校正后估算出点患病率。对发病有关的危险因素作单因素和多因素分析,并对部分     

Randomized clinical trial: Effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome

ObjectivesIrritable bowel syndrome (IBS) is a common diagnosis in gastroenterology. Its etiology is unknown and therapeutic options limited. Trials suggest probiotics may be beneficial. The aim of this study was to assess the symptomatic efficacy of Lactobacillus plantarum 299 v (L. plantarum 299 v) for the relief of abdominal pain in patients with IBS fulfilling Rome II criteria.MethodsThis study was conducted in a referral hospital. Trial participants were randomized to receive either two capsules of L. plantarum 299 v at a dosage of 5 × 10⁹ cfu per capsule or placebo daily for 8 wk. Severity of abdominal pain was assessed using a visual analog scale at each visit and a quality-of-life IBS (QoL-IBS) questionnaire was also completed.ResultsThere was no significant difference in abdominal pain relief between the study and placebo groups (P = 0.800). There was also no difference in QoL- IBS scores between the groups (P = 0.687). Both groups had a significant improvement in abdominal pain scores over the study period, from an average of 251.55 to 197.90 (P < 0.0001) indicating a large placebo effect.ConclusionAn 8-wk treatment with L. plantarum 299 v did not provide symptomatic relief, particularly of abdominal pain and bloating, in patients fulfilling the Rome II criteria.     

411例肠易激综合征患者生活质量状况调查

目的探讨肠易激综合征（IBS）患者的生活质量状况。方法在西安市2所综合医院选取连续的411例IBS患者，其SF-36量表中8个维度的得分以及生理功能总分和心理功能总分与430名健康对照者的得分相比较。结果IBS患者在SF-36量表所有8项维度的得分比健康对照者显著降低（P〈0．001），得分最低的维度是总体健康和情感职能，分别为33．5±16．9、40．8±25．1。IBS患者生理功能总分和心理功能总分也显著降低（P〈0．001）。结论IBS患者生活质量明显受损。分析结果有助于更好了解IBS对患者功能和健康的影响。     

肠易激综合征患者发病危险因素调查研究

目的：探讨影响肠易激综合征（ IBS）发病的危险因素,为早期预防和干预提供依据。方法采用病例对照的研究方法,将确诊的90例IBS患者作为病例组,同时收集非消化系统疾病患者90例作为对照组;对所有病例进行问卷调查,采用单因素和多因素分析IBS发病的危险因素。结果单因素分析结果显示,酗酒史、喜辛辣食物、喜油炸食物、喜腌制食品、胃肠道感染史、家族性腹泻史、长期服药史、长期紧张状态、失眠、疲劳程度、心情焦虑、心情抑郁、性格内向、敏感性格等因素对IBS存在相关性;多因素分析结果显示：酗酒史（OR＝3．294）、喜辛辣食物（OR＝3．927）、胃肠道感染史（OR＝4．884）、长期服药史（OR＝5．155）、长期紧张状态（OR＝2．656）、失眠（OR＝8．474）、心情焦虑（OR＝2．433）、性格内向（ OR＝1．958）。结论影响肠易激综合征发病的独立危险因素较多,应针对这些高危因素制订有效干预措施。     

匹维溴铵联合谷维素治疗老年肠易激综合征临床疗效观察

目的探讨匹维溴铵联合谷维素治疗老年肠易激综合征的临床疗效。方法将73例老年肠易激综合征患者随机分为试验组（n=37例）和对照组（n：36例）。试验组给予匹维溴铵治疗,3次／d,每次50mg,另给予谷维素治疗,3次／d,每次30mg。对照组只给予匹维溴铵治疗,3次／d,每次50mg。两组均以30d为1个疗程,评估两组的I临床治疗效果。结果试验组和对照组的显效率分别62．3％和27．8％,两组比较差异有统计学意义（χ2=6．37,P〈0．05）。试验组和对照组的总有效率分别89．2％和61．1％,两组比较差异亦有统计学意义（χ2=7．45,P〈0．05）。两组均未出现明显不良反应,患者耐受性好。结论匹维溴铵联合谷维素治疗老年肠易激综合征疗效明显,不良反应轻微,值得临床推广。     

行为疗法对肠易激综合征患者生活质量的影响

目的探讨行为疗法对肠易激综合征(IBS)患者生活质量的影响。方法 60例IBS患者随机分为对照组和干预组(各30例),常规药物治疗,干预组加用行为疗法干预。于实验前及实验后6周末评估生活质量。结果两组均完成治疗和问卷调查。干预组总有效率(100.0)高于对照组(60.0),干预组腹痛、腹胀、便秘、黏液便症状明显减轻,优于对照组,差异均有统计学意义(P<0.05,P<0.01)。结论行为疗法能有效改善IBS患者的临床症状,提高其生活质量。     

Quality of life of patients with irritable bowel syndrome in Korea

Objective  The impact of irritable bowel syndrome (IBS) on HRQOL has been widely studied in the West. However, there are few data from Asian countries. The aim of this study was to assess the health-related quality of life (HRQOL) of patients suffering from IBS in Korea. Methods  Consecutive patients from six secondary and six tertiary medical centers in Korea were enrolled and completed self-administered questionnaires on sociodemographics and IBS-associated symptoms. HRQOL was assessed using the generic Short Form 36 (SF-36) and the disease-specific IBS-QOL questionnaires. Results  Of the 932 patients with abdominal pain and bowel symptoms, 664 IBS patients who fulfilled the Rome II criteria were analyzed. On all eight SF-36 scales, IBS patients had a significantly worse HRQOL than the general population (P < 0.01). The overall score for the IBS-QOL was 74.2. The health concern domain was most affected (mean score 64.2), and the sexual domain (mean score 86.7) was least affected in the IBS-QOL. Significant impairment of HRQOL was only observed in patients with severe symptoms both in the generic and specific HRQOL measurement, whereas patients with mild and moderate symptoms showed only mild impairment (P < 0.01). Female patients reported a significantly lower HRQOL than male patients (P < 0.05), but the difference was minimal. The IBS-QOL was significantly associated with female gender, total symptom score, self-reported symptom severity, and level of education in the multivariate analysis. Conclusions  IBS-related symptoms had a great effect on the HRQOL of Korean patients. These results and the considerable prevalence of IBS in Korea indicate that IBS has a substantial social impact in this country.     

Dietary modulation of gut microbiota for the relief of irritable bowel syndrome

Irritable bowel syndrome (IBS) is a frequently diagnosed gastrointestinal (GI) disorder characterized by recurrent abdominal pain, bloating, and changes in the stool form or frequency without any structural changes and overt inflammation. It is not a life-threatening condition but causes a considerable level of discomfort and distress. Among the many pathophysiologic factors, such as altered GI motility, visceral hypersensitivity, and low-grade mucosal inflammation, as well as other immunologic, psychologic, and genetic factors, gut microbiota imbalance (dysbiosis), which is frequently found in IBS, has been highlighted as an etiology of IBS. Dysbiosis may affect gut mucosal homeostasis, immune function, metabolic regulation, and even visceral motor function. As diet is shown to play a fundamental role in the gut microbiota profile, this review discusses the influence of diet on IBS occurring through the modulation of gut microbiota. Based on previous studies, it appears that dietary modulation of the gut microbiota may be effective for the alleviation of IBS symptoms and, also an effective IBS management strategy based on the underlying mechanism; especially because, IBS currently has no specific treatment owing to its uncertain etiology.